RxDoctor Payments DataLook up a doctor →

Muhammad Hussain, DO

Medical Oncology · Plymouth, INNPI 1669800728

Payments from drug & device makers

$10,416in general payments, 2019–2025

Across 234 payments — averaging $44.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • E.r. Squibb & Sons, L.L.C.$1K
  • AstraZeneca$530
  • Novartis$413
  • Genentech USA, Inc.$379
  • Merck$278
  • plus $3K from 38 others

What the payments were for

  • Consulting fees$3,12030%
  • Travel & lodging$1,15911%
  • Food & beverage$5,99758%
  • Education$1411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,416 in reported general payments places this provider in the 50th percentile of 67 medical oncology providers in Indiana.

See all medical oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$2,263,552
Medicare patients
456
Services billed
121,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate56$748,609
RevlimidLenalidomide30$483,424
IbrancePalbociclib21$326,676
OrserduElacestrant Hcl12$281,396
XtandiEnzalutamide20$280,150
NubeqaDarolutamide18$240,789
CalquenceAcalabrutinib Maleate14$197,302
EliquisApixaban153$136,299
XareltoRivaroxaban54$69,803
Abiraterone Acetate13$3,802
Exemestane18$3,121
Letrozole85$1,697
Gabapentin48$1,480
Ondansetron OdtOndansetron54$797
Pantoprazole Sodium77$685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$73$748,60956 claims
Bristol Myers SquibbRevlimid$250$483,42430 claims
PfizerIbrance, Eliquis$117$462,975174 claims
Stemline Therapeutics Inc.Orserdu$43$281,39612 claims
Astellas Pharma US IncXtandi$57$280,15020 claims
BayerNubeqa$113$240,78918 claims
AstraZenecaCalquence$530$197,30214 claims
Johnson & JohnsonXarelto$4,451$69,80354 claims
AbbVieSynthroid$259$47228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 67 medical oncology providers in Indiana.

Other medical oncology in Plymouth

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →